275 related articles for article (PubMed ID: 35527786)
1. Tyrosine kinase inhibitors in sarcoma treatment.
Kyriazoglou A; Gkaralea LE; Kotsantis I; Anastasiou M; Pantazopoulos A; Prevezanou M; Chatzidakis I; Kavourakis G; Economopoulou P; Nixon IF; Psyrri A
Oncol Lett; 2022 Jun; 23(6):183. PubMed ID: 35527786
[TBL] [Abstract][Full Text] [Related]
2. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.
Sethi TK; Keedy VL
Curr Treat Options Oncol; 2016 Feb; 17(2):11. PubMed ID: 26931561
[TBL] [Abstract][Full Text] [Related]
3. The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib.
Wilding CP; Elms ML; Judson I; Tan AC; Jones RL; Huang PH
Expert Rev Anticancer Ther; 2019 Nov; 19(11):971-991. PubMed ID: 31665941
[No Abstract] [Full Text] [Related]
4. Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas.
Shor AC; Agresta SV; D'Amato GZ; Sondak VK
Cancer Control; 2008 Jan; 15(1):47-54. PubMed ID: 18094660
[TBL] [Abstract][Full Text] [Related]
5. Treatment options in unresectable soft tissue and bone sarcoma of the extremities and pelvis - a systematic literature review.
Smolle MA; Szkandera J; Andreou D; Palmerini E; Bergovec M; Leithner A
EFORT Open Rev; 2020 Nov; 5(11):799-814. PubMed ID: 33312707
[TBL] [Abstract][Full Text] [Related]
6. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself.
Yang QK; Chen T; Wang SQ; Zhang XJ; Yao ZX
Angiogenesis; 2020 Aug; 23(3):279-298. PubMed ID: 32333216
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas.
Homet Moreno B; Garralda Cabanas E; Hitt R
Clin Transl Oncol; 2010 Jul; 12(7):468-72. PubMed ID: 20615823
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
Shor AC; Keschman EA; Lee FY; Muro-Cacho C; Letson GD; Trent JC; Pledger WJ; Jove R
Cancer Res; 2007 Mar; 67(6):2800-8. PubMed ID: 17363602
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies for the treatment of soft tissue sarcoma.
Fuchs JW; Schulte BC; Fuchs JR; Agulnik M
Front Oncol; 2023; 13():1122508. PubMed ID: 36969064
[TBL] [Abstract][Full Text] [Related]
10. Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma.
Kopp HG; Patel S; Brücher B; Hartmann JT
Am J Clin Dermatol; 2008; 9(4):207-17. PubMed ID: 18572972
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis.
Saerens M; Brusselaers N; Rottey S; Decruyenaere A; Creytens D; Lapeire L
Eur J Cancer; 2021 Jul; 152():165-182. PubMed ID: 34107450
[TBL] [Abstract][Full Text] [Related]
12. Molecular targeted therapy for advanced or metastatic soft tissue sarcoma.
Yuan J; Li X; Yu S
Cancer Control; 2021; 28():10732748211038424. PubMed ID: 34844463
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas.
Napolitano A; Ostler AE; Jones RL; Huang PH
Cells; 2021 Jun; 10(6):. PubMed ID: 34204560
[TBL] [Abstract][Full Text] [Related]
14. Opportunities for improving the therapeutic ratio for patients with sarcoma.
Wunder JS; Nielsen TO; Maki RG; O'Sullivan B; Alman BA
Lancet Oncol; 2007 Jun; 8(6):513-24. PubMed ID: 17540303
[TBL] [Abstract][Full Text] [Related]
15. [Is there a magic bullet for sarcomas? : Personalised treatment for maligant tumours of bone and soft tissue].
Scheipl S; Liegl-Atzwanger B; Szkandera J; Rinner B; Viertler C; Friesenbichler J; Bergovec M; Leithner A
Orthopade; 2019 Sep; 48(9):776-783. PubMed ID: 31396640
[TBL] [Abstract][Full Text] [Related]
16. Novel Insights into the Immunotherapy of Soft Tissue Sarcomas: Do We Need a Change of Perspective?
Ozaniak A; Vachtenheim J; Lischke R; Bartunkova J; Strizova Z
Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440139
[TBL] [Abstract][Full Text] [Related]
17. Targeting angiogenesis for the treatment of sarcoma.
Balasubramanian L; Evens AM
Curr Opin Oncol; 2006 Jul; 18(4):354-9. PubMed ID: 16721130
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic assessment of postradiation sarcomas: KIT as a potential treatment target.
Komdeur R; Hoekstra HJ; Molenaar WM; Van Den Berg E; Zwart N; Pras E; Plaza-Menacho I; Hofstra RM; Van Der Graaf WT
Clin Cancer Res; 2003 Aug; 9(8):2926-32. PubMed ID: 12912938
[TBL] [Abstract][Full Text] [Related]
19. Heparanase: A Potential Therapeutic Target in Sarcomas.
Cassinelli G; Lanzi C
Adv Exp Med Biol; 2020; 1221():405-431. PubMed ID: 32274719
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.
Nathenson MJ; Conley AP; Sausville E
Oncologist; 2018 Jan; 23(1):71-83. PubMed ID: 28935774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
